Bracco Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRACCO, and when can generic versions of BRACCO drugs launch?
BRACCO has forty approved drugs.
There are three US patents protecting BRACCO drugs.
There are thirty-seven patent family members on BRACCO drugs in twelve countries and seventy-four supplementary protection certificates in eight countries.
Drugs and US Patents for Bracco
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | ISOVUE-300 | iopamidol | INJECTABLE;INJECTION | 018735-002 | Dec 31, 1985 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-002 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | ORAGRAFIN SODIUM | ipodate sodium | CAPSULE;ORAL | 012967-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | ISOVUE-M 300 | iopamidol | INJECTABLE;INJECTION | 018735-004 | Dec 31, 1985 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bracco
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bracco | ISOVUE-200 | iopamidol | INJECTABLE;INJECTION | 020327-001 | Oct 12, 1994 | 4,001,323 | ⤷ Try a Trial |
Bracco | PROHANCE MULTIPACK | gadoteridol | INJECTABLE;INJECTION | 021489-001 | Oct 9, 2003 | 5,474,756 | ⤷ Try a Trial |
Bracco | PROHANCE MULTIPACK | gadoteridol | INJECTABLE;INJECTION | 021489-001 | Oct 9, 2003 | 4,885,363 | ⤷ Try a Trial |
Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 020327-002 | Oct 12, 1994 | 4,001,323 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bracco Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 113811335 | ⤷ Try a Trial |
Canada | 3098380 | ⤷ Try a Trial |
Israel | 288094 | ⤷ Try a Trial |
South Korea | 102624471 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bracco Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2203431 | 2015/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
1556389 | SPC/GB16/002 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZANE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR A SULFURIC ACID SALT.; REGISTERED: UK EU/1/15/1032 20150922 |
1713823 | 1490064-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
1666481 | 17C1031 | France | ⤷ Try a Trial | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.